Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Xbiome Strikes NewCo‑Style Technology Collaboration with Biogent Therapeutics for AI‑Driven Bispecific Antibody Development

Fineline Cube Aug 14, 2026
Company Deals

ACROBiosystems and Bailinke Pharmaceutical Form Strategic Partnership to Build AI‑Empowered Affinity Purification Solutions

Fineline Cube Aug 14, 2026
Company Deals

IASO Biotherapeutics Completes Acquisition of MediSix Therapeutics – Adding PEBL‑Based CAR‑T Cell Therapy Platform for T‑Cell Malignancies

Fineline Cube Aug 14, 2026
Company Deals

Hybio Pharmaceutical Grants Wansheng Pharmaceutical Exclusive China License for Semaglutide’s Glycemic Control Indication in Up-to-RMB 182.5 Million Deal

Fineline Cube Aug 13, 2026
Company Deals

Insilico Medicine and THPharma Launch AI Research Collaboration to Build ‘Reverse Translation’ Drug Discovery Strategy Around Phase 3 Candidate THP-001

Fineline Cube Aug 13, 2026
Policy / Regulatory

NMPA Releases Draft Implementation Rules for the National Key R&D Program – Public Comment Open Through 12 Sept 2026

Fineline Cube Aug 14, 2026
Company Drug

CDE Adds Two New Drugs to Rare Disease “Caring Program – Extension” Pilot – SZJ0107 and JAB-8263 Included

Fineline Cube Aug 14, 2026
Company Drug

Celgenyx Secures FDA IND Clearance for CG101 Off‑the‑Shelf iPSC‑Derived Cell Therapy in Acute Myeloid Leukemia – Multicenter Phase I Study to Begin

Fineline Cube Aug 14, 2026
Company Drug

Ascletis Pharma’s ASC40 Earns FDA Breakthrough Therapy Designation for Fibrotic MASH

Fineline Cube Oct 10, 2024

China-based Ascletis Pharma Inc. (HKG: 1672) has announced that ASC40 (denifanstat), a fatty acid synthase...

Company Deals

HitGen Inc. Partners with Ablink Biotech to Develop Antibody-Oligonucleotide Conjugates

Fineline Cube Oct 10, 2024

China-based HitGen Inc. (SHA: 688222) has entered into a partnership with compatriot firm Ablink Biotech...

Company Drug

Sichuan Biokin’s BL-B01D1 Earns Breakthrough Therapy Designation for Esophageal Cancer from China’s CDE

Fineline Cube Oct 10, 2024

Sichuan Biokin Pharmaceutical Co., Ltd (SHA: 688506) has announced that its bispecific antibody drug conjugate...

Company Drug

Merck’s Keytruda Meets Primary Endpoint in Phase III Study for Head and Neck Cancer

Fineline Cube Oct 10, 2024

US pharmaceutical giant Merck & Co., Inc. (MRK, NYSE: MRK) has announced that the Phase...

Company Drug

Boehringer Ingelheim’s Survodutide Earns FDA Breakthrough Therapy Designation for MASH Treatment

Fineline Cube Oct 10, 2024

German pharmaceutical company Boehringer Ingelheim has received breakthrough therapy designation (BTD) from the US Food...

Company

Eli Lilly Appoints Thomas J. Fuchs as First Chief AI Officer to Lead AI Initiatives

Fineline Cube Oct 10, 2024

Eli Lilly and Company (NYSE: LLY) has announced the appointment of Thomas J. Fuchs, Dr.sc.,...

Company Deals

Zephyrm Bioscience Limited Files for IPO on Hong Kong Stock Exchange

Fineline Cube Oct 9, 2024

China-based Zephyrm Bioscience Limited, a biopharmaceutical company specializing in the development of novel pluripotent stem...

Company Drug

Pfizer Halts Development of Sisunatovir, an RSV Antiviral, After Phase II/III Trials

Fineline Cube Oct 9, 2024

U.S. pharmaceutical giant Pfizer (NYSE: PFE) has decided to discontinue the development of sisunatovir, an...

Company Drug

Biogen’s China Unit Gets Conditional NMPA Nod for Qalsody (Tofersen) in ALS Treatment

Fineline Cube Oct 9, 2024

Biogen (NASDAQ: BIIB)’s Chinese subsidiary has announced that it has received conditional approval from the...

Company Drug

Joincare Pharmaceutical Secures NMPA Approval for Triptorelin Microspheres to Treat Endometriosis

Fineline Cube Oct 9, 2024

China-based Joincare Pharmaceutical Group Industry Co., Ltd (SHA: 600380) has announced that it has received...

Company Drug

CSPC Pharmaceutical Secures NMPA Approval for Omalizumab Biosimilar

Fineline Cube Oct 9, 2024

China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) has announced that it has received marketing approval...

Company Deals

Ningbo Menovo Pharmaceutical Partners with Nanjing Huawe Medicine for High-End Product Development

Fineline Cube Oct 9, 2024

Ningbo Menovo Pharmaceutical Co., Ltd (SHA: 603538) has entered into a strategic partnership with Nanjing...

Company Drug

CSPC Pharmaceutical’s ADC CPO301 Earns Second Fast-Track Designation in the US for NSCLC Treatment

Fineline Cube Oct 9, 2024

China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) has announced that its best-in-class antibody drug conjugate...

Company Deals Drug

Bio-Thera Solutions Ltd Strikes Licensing Deal with Gedeon Richter for BAT1706 Biosimilar

Fineline Cube Oct 9, 2024

Guangzhou-based Bio-Thera Solutions Ltd has announced a licensing agreement with Hungary’s Gedeon Richter Plc for...

Company Drug

Jiangsu Aidea Pharmaceutical Secures NMPA Approval for Expanded Indication of Fubangde in HIV Treatment

Fineline Cube Oct 9, 2024

China-based Jiangsu Aidea Pharmaceutical Co., Ltd (SHA: 688488) has announced that the National Medical Products...

Company Drug

Ascentage Pharma Receives Approval for Two Phase III Trials of APG-2449 in NSCLC

Fineline Cube Oct 9, 2024

China-based biopharmaceutical company Ascentage Pharma (HKG: 6855) has announced that it has received approval from...

Company Medical Device

MicroPort Endovascular MedTech’s Fiber Wool Plug Spring Coil Gains NMPA Marketing Approval

Fineline Cube Oct 9, 2024

Shanghai MicroPort Endovascular MedTech Co., Ltd (SHA: 688016) has received marketing approval from the National...

Policy / Regulatory

NMPA Expands Generic Quality Consistency Evaluation with 83rd Batch of Reference Drugs

Fineline Cube Oct 9, 2024

The National Medical Products Administration (NMPA) in China has announced the release of the 83rd...

Company Deals

Kailera Therapeutics Emerges with USD 400 Million in Series A Funding for Anti-Obesity Pipeline

Fineline Cube Oct 8, 2024

Kailera Therapeutics, a newly launched US-based biotechnology company, secured USD 400 million in Series A...

Company Deals

AstraZeneca Strikes Exclusive Licensing Deal with CSPC Pharma for Oral Lp(a) Disruptor

Fineline Cube Oct 8, 2024

UK pharmaceutical giant AstraZeneca (NASDAQ: AZN, LON: AZN) has announced the signing of an exclusive...

Posts pagination

1 … 330 331 332 … 708

Recent updates

  • Xbiome Strikes NewCo‑Style Technology Collaboration with Biogent Therapeutics for AI‑Driven Bispecific Antibody Development
  • CDE Adds Two New Drugs to Rare Disease “Caring Program – Extension” Pilot – SZJ0107 and JAB-8263 Included
  • ACROBiosystems and Bailinke Pharmaceutical Form Strategic Partnership to Build AI‑Empowered Affinity Purification Solutions
  • Celgenyx Secures FDA IND Clearance for CG101 Off‑the‑Shelf iPSC‑Derived Cell Therapy in Acute Myeloid Leukemia – Multicenter Phase I Study to Begin
  • NMPA Releases Draft Implementation Rules for the National Key R&D Program – Public Comment Open Through 12 Sept 2026
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Xbiome Strikes NewCo‑Style Technology Collaboration with Biogent Therapeutics for AI‑Driven Bispecific Antibody Development

Company Drug

CDE Adds Two New Drugs to Rare Disease “Caring Program – Extension” Pilot – SZJ0107 and JAB-8263 Included

Company Deals

ACROBiosystems and Bailinke Pharmaceutical Form Strategic Partnership to Build AI‑Empowered Affinity Purification Solutions

Company Drug

Celgenyx Secures FDA IND Clearance for CG101 Off‑the‑Shelf iPSC‑Derived Cell Therapy in Acute Myeloid Leukemia – Multicenter Phase I Study to Begin

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.